Finch Therapeutics Group, Inc. (FNCH)


+0.23 (+10.95%)
Symbol FNCH
Price $2.33
Beta 0.000
Volume Avg. 0.96M
Market Cap 110.813M
Shares () -
52 Week Range 1.712-17.39
1y Target Est -
DCF Unlevered FNCH DCF ->
DCF Levered FNCH LDCF ->
ROE -33.13% Strong Sell
ROA -33.59% Strong Sell
Operating Margin -
Debt / Equity 13.82% Neutral
P/E -
P/B 0.62 Buy


Consensus EPS

Upgrades & Downgrades

Latest FNCH news

Mr. Mark Burnham Smith
NASDAQ Global Select

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.